Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016/09/17 by Ajaikumar B. Kunnumakkara, Ajaikumar B Kunnumakkara, Devivasha Bordoloi +6 · 1,034 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics · #Adverse effect #Bioinformatics #Biology #Clinical trial #Curcuma #Curcumin #Curcumin's Biomedical Applications #Ginger and Zingiberaceae research #Internal medicine #Medicine #Nutraceutical #Pathology #Pharmacology #Piperaceae Chemical and Biological Studies #Resveratrol #Tolerability #Traditional medicine
paper · pdf · doi:10.1111/bph.13621
published in British Journal of Pharmacology 174(11), 1325-1348 (Wiley)
openalex publication_date 2016/09/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
Curcumin, a yellow pigment in the Indian spice Turmeric (Curcuma longa), which is chemically known as diferuloylmethane, was first isolated exactly two centuries ago in 1815 by two German Scientists, Vogel and Pelletier. However, according to the pubmed database, the first study on its biological activity as an antibacterial agent was published in 1949 in Nature and the first clinical trial was reported in The Lancet in 1937. Although the current database indicates almost 9000 publications on curcumin, until 1990 there were less than 100 papers published on this nutraceutical. At the molecular level, this multitargeted agent has been shown to exhibit anti-inflammatory activity through the suppression of numerous cell signalling pathways including NF-κB, STAT3, Nrf2, ROS and COX-2. Numerous studies have indicated that curcumin is a highly potent antimicrobial agent and has been shown to be active against various chronic diseases including various types of cancers, diabetes, obesity, cardiovascular, pulmonary, neurological and autoimmune diseases. Furthermore, this compound has also been shown to be synergistic with other nutraceuticals such as resveratrol, piperine, catechins, quercetin and genistein. To date, over 100 different clinical trials have been completed with curcumin, which clearly show its safety, tolerability and its effectiveness against various chronic diseases in humans. However, more clinical trials in different populations are necessary to prove its potential against different chronic diseases in humans. This review's primary focus is on lessons learnt about curcumin from clinical trials. LINKED ARTICLES: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc.
Cited by
- AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
- Fighting Liver Fibrosis with Naturally Occurring Antioxidants
- Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL‐4Rα‐Jak1‐STAT6 and Jagged1/Jagged2 ‐Notch1/Notch2 pathways in asthmatic mice
- Curcumin combined with photodynamic therapy, promising therapies for the treatment of cancer
- Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease. [europepmc]
- Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. [europepmc]
- Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease. [europepmc]
- Chronic diseases, inflammation, and spices: how are they linked? [europepmc]
- The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? [europepmc]
- Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer. [europepmc]
- AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. [europepmc]
- A Review of Curcumin and Its Derivatives as Anticancer Agents. [europepmc]
- Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment. [europepmc]
- Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. [europepmc]
- An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases. [europepmc]
- Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review. [europepmc]
- Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. [europepmc]
- Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin. [europepmc]
- Antioxidant Potential of Curcumin-A Meta-Analysis of Randomized Clinical Trials. [europepmc]
- Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells. [europepmc]
- The Role of Curcumin in Cancer Treatment. [europepmc]
- Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer's Disease: The Role of Antioxidants in Prevention and Treatment. [europepmc]
- Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. [europepmc]
- Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. [europepmc]
- The Multifaceted Role of Curcumin in Advanced Nanocurcumin Form in the Treatment and Management of Chronic Disorders. [europepmc]
- The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative Stress-Related Eye Diseases. [europepmc]
- Curcumin: Biological Activities and Modern Pharmaceutical Forms. [europepmc]
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin. [europepmc]
- Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? [europepmc]
Related